Suomalainen: nothing to disclose, Sami Curtze: nothing to disclose, Tuomas Lumikari: nothing to disclose, Jani Pirinen: nothing to disclose, Daniel Gordin: nothing to disclose, Petra Ijs: nothing to disclose, Sija Rty: nothing to disclose, Mika Lehto: nothing to disclose, Jukka Putaala: nothing to disclose E-Posters - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.06 - CARDIOEMBOLISM & HEART-BRAIN INTERACTIONS P2371 - ESOC25-1381 STROKE UNIT TELEMETRY REVEALS DISTINCT EPISODE DYNAMICS ASSOCIATED WITH ATRIAL FIBRILLATION BURDEN AFTER ACUTE ISCHEMIC STROKE Markus Klammer 1,2,3 , Helena Stengl 1,2,3 , Alexander Nelde 1,3 , Maximilian Schls 1,3 , Andreas Meisel 1,2,3 , Franziska Scheibe 1,4 , Christian Nolte 1,2,3 , Matthias Endres, Christian Meisel 2,3,4 , Jan Scheitz 1,2,3 1 Department of Experimental Neurology - Charite Universittsmedizin Berlin, Berlin, Germany, 2 Center of Stroke Research Berlin, Berlin, Germany, 3 Berlin Institute of Health (BIH), Berlin, Germany, 4 NeuroCure Cluster of Excellence, Charit-Universittsmedizin Berlin, Berlin, Germany Background and Aims: Atrial fibrillation (AF) burden is a key prognostic factor for AF-related first and recurrent stroke, but its characteristics and AF-associated heart rate (HR) in the early post-stroke phase are not well understood
women of childbearing potential need reliable contraception
Microdosing Compounded Tirzepatide+ offers a gentler, steadier approach that aligns with these long-term goals
Tirzepatide coverage: Federal Medicare insurance plans Federal insurance programs follow a different set of rules than most private plans, which affects how tirzepatide is covered
